GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ovation Science Inc (XCNQ:OVAT) » Definitions » EV-to-Revenue

Ovation Science (XCNQ:OVAT) EV-to-Revenue : 26.92 (As of May. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ovation Science EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ovation Science's enterprise value is C$1.67 Mil. Ovation Science's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.06 Mil. Therefore, Ovation Science's EV-to-Revenue for today is 26.92.

The historical rank and industry rank for Ovation Science's EV-to-Revenue or its related term are showing as below:

XCNQ:OVAT' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.32   Med: 11.21   Max: 173.64
Current: 26.92

During the past 7 years, the highest EV-to-Revenue of Ovation Science was 173.64. The lowest was 2.32. And the median was 11.21.

XCNQ:OVAT's EV-to-Revenue is ranked worse than
93.27% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.3 vs XCNQ:OVAT: 26.92

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-24), Ovation Science's stock price is C$0.045. Ovation Science's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00. Therefore, Ovation Science's PS Ratio for today is 45.00.


Ovation Science EV-to-Revenue Historical Data

The historical data trend for Ovation Science's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovation Science EV-to-Revenue Chart

Ovation Science Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 12.90 11.85 4.95 5.41 21.44

Ovation Science Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.41 4.41 4.98 12.77 21.44

Competitive Comparison of Ovation Science's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovation Science's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ovation Science's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ovation Science's EV-to-Revenue falls into.



Ovation Science EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Ovation Science's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1.669/0.062
=26.92

Ovation Science's current Enterprise Value is C$1.67 Mil.
Ovation Science's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovation Science  (XCNQ:OVAT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Ovation Science's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.045/0.001
=45.00

Ovation Science's share price for today is C$0.045.
Ovation Science's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovation Science EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ovation Science's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovation Science (XCNQ:OVAT) Business Description

Traded in Other Exchanges
Address
625 Howe Street, Suite 1140, Vancouver, BC, CAN, V6C 2T6
Ovation Science Inc is a Canada-based company mainly engaged in the business of sub-licensing rights to use Invisicare, a patented drug delivery technology used in topical and transdermal skin products containing hemp seed oil and cannabis products. The company also holds the right to manufacture, distribute, sell, market, sub-license and promote products formulated with Invisicare and containing cannabis products including cannabinoids, hemp seed oil and any synthetic derivatives of cannabis. It also develops formulas for skin product lines including topical and transdermal creams and lotions containing hemp seed oil and cannabis.
Executives
David K. Ryan Director

Ovation Science (XCNQ:OVAT) Headlines

No Headlines